Watch BICX. Know when insiders buy.
One email the day a filing lands. Free.
BICX
BioCorRx Inc.
0.24
−0.01 −4.00%
USD · close Oct 20
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $7.1MP/E —DIV YIELD —FCF YIELD —REV TTM $787K +151.2%NET INCOME −$3.2MNET CASH $111K52W 0.15 – 0.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $88K | −50.6% | -64.8% | −$1.5M | −$965K | — | -0.03 | −$440K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $215K | +59.0% | 88.3% | −$956K | −$831K | — | -0.03 | −$433K | — | — | May 15 |
| Q4 2025 · Dec 31derived | −$151K | — | — | −$534K | $553K | — | 0.05 | −$848K | — | — | Mar 31 |
| Q3 2025 · Sep 30 | $635K | — | — | −$1.9M | −$1.9M | — | -0.11 | −$634K | — | — | Mar 31 |
| Q2 2025 · Jun 30 | $178K | +4306.4% | 100.0% | −$1.4M | −$1.2M | — | -0.07 | −$126K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $135K | +3626.5% | 100.0% | −$938K | −$841K | — | -0.06 | −$690K | — | — | May 15 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$1.1M | −$1.2M | — | -0.08 | −$247K | — | — | Mar 31 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$1.7M | −$1.5M | — | -0.14 | −$358K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | $4K | — | 100.0% | −$1.4M | −$1.2M | — | -0.13 | −$152K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $4K | — | 54.0% | −$969K | −$1.2M | — | — | −$340K | — | — | May 15 |
| Q4 2023 · Dec 31derived | $19K | — | 31.1% | −$823K | −$969K | — | — | −$534K | — | — | Mar 31 |
| Q3 2023 · Sep 30 | $10K | — | 61.7% | −$962K | −$867K | — | — | −$351K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $797K | — | −$4.8M | −$3.4M | -431.5% | -0.19 | −$2.3M | — | — | — | — |
| FY2024 · to Dec 31 | $8K | 78.3% | −$5.1M | −$5.1M | -66616.1% | -0.49 | −$1.1M | — | — | — | — |
| FY2023 · to Dec 31 | $89K | 59.6% | −$3.8M | −$3.8M | -4228.9% | — | −$1.9M | — | — | — | — |
| FY2022 · to Dec 31 | $214K | 92.9% | −$4.7M | −$4.4M | -2046.8% | — | −$2M | $0 | −$2M | — | — |
| FY2021 · to Dec 31 | $48K | 87.8% | −$5.5M | −$5.2M | -10794.3% | -0.81 | −$3.5M | $2K | −$3.5M | — | — |
| FY2020 · to Dec 31 | $123K | 21.8% | −$7.5M | −$3.5M | -2859.6% | -0.65 | −$2.2M | $0 | −$2.2M | — | — |
Every number comes from BioCorRx Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.